Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin and Tislelizumab in Metastatic MSI-H Colorectal Cancer
NCT07076823Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of canagliflozin in colorectal cancer (CRC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Adverse Effect at 1 year. Started Jul 2025; status: recruiting.
02
Drugs
canagliflozin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07076823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076823.